115 related articles for article (PubMed ID: 15536434)
1. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.
Pace E; Gagliardo R; Melis M; La Grutta S; Ferraro M; Siena L; Bonsignore G; Gjomarkaj M; Bousquet J; Vignola AM
J Allergy Clin Immunol; 2004 Nov; 114(5):1216-23. PubMed ID: 15536434
[TBL] [Abstract][Full Text] [Related]
2. Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
Goleva E; Dunlap A; Leung DY
J Allergy Clin Immunol; 2004 Jul; 114(1):183-91. PubMed ID: 15241363
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.
Usmani OS; Ito K; Maneechotesuwan K; Ito M; Johnson M; Barnes PJ; Adcock IM
Am J Respir Crit Care Med; 2005 Sep; 172(6):704-12. PubMed ID: 15860753
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone.
Katial RK; Bernstein D; Prazma CM; Lincourt WR; Stempel DA
Allergy Asthma Proc; 2011; 32(2):127-36. PubMed ID: 21189151
[TBL] [Abstract][Full Text] [Related]
5. Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.
Mortaz E; Rad MV; Johnson M; Raats D; Nijkamp FP; Folkerts G
J Mol Med (Berl); 2008 Sep; 86(9):1045-56. PubMed ID: 18600309
[TBL] [Abstract][Full Text] [Related]
6. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy.
Hagiwara M; Delea TE; Stanford RH; Stempel DA
Allergy Asthma Proc; 2010; 31(3):203-10. PubMed ID: 20534183
[TBL] [Abstract][Full Text] [Related]
7. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Hagiwara M; Delea TE; Stanford RH
Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
9. Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB.
Baouz S; Giron-Michel J; Azzarone B; Giuliani M; Cagnoni F; Olsson S; Testi R; Gabbiani G; Canonica GW
Int Immunol; 2005 Nov; 17(11):1473-81. PubMed ID: 16210331
[TBL] [Abstract][Full Text] [Related]
10. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone propionate and Salmeterol combination induces SOCS-3 expression in airway epithelial cells.
Nasreen N; Khodayari N; Sukka-Ganesh B; Peruvemba S; Mohammed KA
Int Immunopharmacol; 2012 Jan; 12(1):217-25. PubMed ID: 22155101
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
13. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma.
Murray CS; Custovic A; Lowe LA; Aldington S; Williams M; Beasley R; Woodcock A
Allergy Asthma Proc; 2010; 31(5):415-21. PubMed ID: 20929609
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
Edwards MR; Haas J; Panettieri RA; Johnson M; Johnston SL
J Biol Chem; 2007 May; 282(21):15366-75. PubMed ID: 17395587
[TBL] [Abstract][Full Text] [Related]
15. Adding salmeterol to fluticasone propionate or increasing the dose of fluticasone propionate in patients with asthma.
Delea TE; Hagiwara M; Stempel DA; Stanford RH
Allergy Asthma Proc; 2010; 31(3):211-8. PubMed ID: 20615321
[TBL] [Abstract][Full Text] [Related]
16. Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
Pavord I; Woodcock A; Parker D; Rice L;
Respir Res; 2007 Sep; 8(1):67. PubMed ID: 17897478
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium.
Kan-O K; Matsumoto K; Inoue H; Fukuyama S; Asai Y; Watanabe W; Kurokawa M; Araya J; Kuwano K; Nakanishi Y
Int Arch Allergy Immunol; 2013; 160(1):27-36. PubMed ID: 22948082
[TBL] [Abstract][Full Text] [Related]
19. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
